Ventripoint Diagnostics Licenses Technology to Lishman Global for China Market

Toronto, Ontario — July 11, 2025 — NewsWall — Ventripoint Diagnostics Ltd. has signed a non-binding term sheet with Lishman Global Inc., granting an exclusive, non-transferable license for Ventripoint technology within Lishman’s echocardiography image platform in China, including Hong Kong and Macao.

Lishman's Chinese subsidiary previously received CFDA approval and a Certificate of Production for the VMS+ product, used for right ventricle analysis. The new license allows Lishman to integrate VMS+ 4.0 within its echocardiography platforms and market the technology in the region. The final license will specify annual minimum volumes upon CFDA approval. Lishman has placed a purchase order for VMS+ components and committed to an investment in Ventripoint.

Hugh MacNaught, President and CEO of Ventripoint, noted the ongoing commitment of their Chinese partners to VMS+ and highlighted the high rate of heart disease and echocardiogram usage in China. Paul Gibson, CTO of Lishman, expressed enthusiasm for integrating VMS+ within their platforms and securing CFDA approval.

Pre-marketing efforts are underway in the Chinese market, targeting 2,500 Tier 1 hospitals and a total of 32,000 hospitals. Lishman Global assists companies in entering the Chinese Market by helping them navigate regulatory approvals and distribution channels in the Chinese medical device market.

Ventripoint is an industry leader in AI applications for echocardiography, providing accurate volumetric cardiac measurements with its VMS products. VMS+ can be used with ultrasound systems from any vendor supported by regulatory approvals in the U.S., Europe, and Canada.

Contact:
Hugh MacNaught
hmacnaught@ventripoint.com
604-671-4201

Source: Ventripoint Diagnostics Ltd.